Esther Kim, MD
Retina Specialist · Santa Ana, CANPI 1649539404
Payments from drug & device makers
Across 591 payments — averaging $620.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$111K
- Apellis Pharmaceuticals, Inc.$90K
- Astellas Pharma US Inc$87K
- Genentech USA, Inc.$42K
- ANI Pharmaceuticals, Inc.$11K
- Regeneron$8K
- plus $18K from 18 others
What the payments were for
- Consulting fees$157,06343%
- Speaking & faculty fees$165,91045%
- Travel & lodging$26,4037%
- Food & beverage$17,3035%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 162 | $111,229 |
| Apellis Pharmaceuticals, Inc. | 96 | $89,781 |
| Astellas Pharma US Inc | 79 | $86,800 |
| Genentech USA, Inc. | 78 | $41,533 |
| ANI Pharmaceuticals, Inc. | 25 | $10,738 |
| Regeneron | 12 | $8,134 |
| Alimera Sciences, Inc. | 23 | $4,010 |
| Ocular Therapeutix, Inc. | 5 | $3,499 |
| Alcon | 8 | $3,156 |
| Neurotech Pharmaceuticals, Inc. | 2 | $2,972 |
| Genentech, Inc. | 5 | $1,646 |
| AbbVie | 37 | $748 |
| Mallinckrodt Hospital Products Inc. | 20 | $516 |
| Notal Vision, Inc. | 2 | $357 |
| Harrow Eye, LLC | 7 | $337 |
| Bausch & Lomb Americas Inc. | 8 | $290 |
| Novartis | 3 | $255 |
| Astellas Pharma Global Development | 3 | $200 |
| Biogen | 4 | $115 |
| Glaukos Corporation | 1 | $113 |
| Oyster Point Pharma, Inc. | 3 | $87 |
| Eyepoint US, Inc. | 3 | $73 |
| Amgen(2 entities) | 3 | $53 |
| Coherus Oncology, Inc. | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$366,680 in reported general payments places this provider in the 80th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 37 | $40,281 |
| XiidraLifitegrast | 36 | $33,740 |
| MieboPerfluorohexyloctane/Pf | 25 | $18,593 |
| Cyclosporine | 40 | $15,036 |
| VevyeCyclosporine | 20 | $14,871 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 34 | $7,674 |
| TyrvayaVarenicline Tartrate | 11 | $6,708 |
| ProlensaBromfenac Sodium | 19 | $6,316 |
| Prednisolone Acetate | 182 | $5,690 |
| Bromfenac Sodium | 40 | $5,451 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $4,932 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $3,925 |
| Loteprednol Etabonate | 21 | $3,296 |
| Ketorolac Tromethamine | 118 | $1,803 |
| MoxifloxacinMoxifloxacin Hcl | 56 | $1,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $290 | $52,33461 claims |
| AbbVieRestasis, Combigan | $748 | $45,21356 claims |
| Harrow Eye, LLCVevye | $337 | $14,87120 claims |
| AlconSimbrinza | $3,156 | $7,67434 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $87 | $6,70811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 187 retina specialist providers in California.
Other retina specialist in Santa Ana
- Dante PieramiciSanta Barbara$15.1M
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Joel PearlmanSacramento$8.3M
- Dilsher DhootSanta Barbara$8.2M
- Ashkan PirouzFullerton$6.9M
- Roger GoldbergWalnut Creek$5M
- Sean AdreanFullerton$2.9M
- Nathan SteinleSanta Barbara$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.